BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mayne Pharma USA Inc. Announces The Launch Of Epirubicin Hydrochloride For Injection


11/6/2006 11:17:43 PM

PARAMUS, N.J., Nov. 6 /PRNewswire/ -- Mayne Pharma (USA) Inc. has announced that it is launching Epirubicin Hydrochloride for Injection (lyophilized) 50mg/vial (30mL). Mayne Pharma intends to follow-up in the near future with the addition of Epirubicin Hydrochloride for Injection (lyophilized) packaged in a 200mg/vial (100mL vial). Mayne Pharma (USA) Inc.'s new drug application for Epirubicin was approved by the U.S. Food and Drug Administration on September 15, 2006.

Epirubicin Hydrochloride for Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

James Hageman, Senior V.P. and Head of U.S. Commercial Operations said "The addition of Epirubicin Hydrochloride for Injection to our product line is a very exciting event because it further enhances our oncology product range which already includes products such as Paclitaxel, Carboplatin, Methotrexate and Mitroxantrone."

Mayne Pharma (USA) is a specialty pharmaceutical company focused on developing, manufacturing and selling a comprehensive range of products to oncology customers in more than 65 countries around the world. The company seeks to augment its growth by accessing additional marketed or development- stage products either through acquisition or partnership. Mayne Pharma generated sales of more than $US800 million in its financial year ended June 30, 2006 and is listed on the Australian Stock Exchange under the symbol 'MYP'. For more information about Mayne Pharma, please visit www.maynepharma.com.

Mayne Pharma (USA) Inc.

CONTACT: Andrew Rowe, Vice President Investor Relations, Mayne PharmaLimited, +44-20-7420-8426, +44-7920-598-353 (mobile),andrew.rowe@maynepharma.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES